TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04430491

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images
Study: NCT01352923

Intervention type: OTHER
Intervention: blood test
Description: preparation of blood platelets
Study: NCT01785342

Intervention type: OTHER
Intervention: Biosample and Imaging Collection
Description: Collection of listed biosamples and CT imaging.
Study: NCT03287960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Once daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily subcutaneous injection
Study: NCT02482727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
Description: A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
Study: NCT03391427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: This group will receive lidocaine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: This group will receive Ketamine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine+ketamine
Description: This group will receive mixture of ketamine and lidocaine infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: This group will receive saline infusion
Study: NCT01099670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Rectal suppository Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Rectal suppository Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Rectal suppository Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Rectal suppository Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04623814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: HEC113995 20mg will be taken orally fasted or with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC113995
Description: HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC113995
Description: HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC113995
Description: HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
Study: NCT01099670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03035175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy
Description: Residents intubate using video laryngoscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Laryngoscopy
Description: Residents intubate without using video laryngoscopy.
Study: NCT00938743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: 40-80 mg atomoxetine once daily, including titration 10 weeks
Study: NCT03475173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSFG-NAVI
Description: laser-speckle blood flow of ocular arteries and veins
Study: NCT00545584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
Study: NCT04623814

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo will be administered fasted or with food for 10 days.
Study: NCT00545584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparator: Diet
Description: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparator: Diet
Description: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparator: Physical Activity
Description: Physical Activity
Study: NCT03710395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and breast milk sampling
Description: At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood and breast milk sampling
Description: At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
Study: NCT04166721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Immunotherapy
Study: NCT01040000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-1C/NEO-102
Description: Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
Study: NCT01011959

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN88
Description: This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN88
Description: This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN88
Description: This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN88
Description: This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN88
Description: This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN88
Description: This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
Study: NCT01689831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
Description: Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
Description: Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reactivity of Aplisol compared to reference standard PPD-S2.
Description: Reference standard PPD-S2 formulated to contain different dose concentrations.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reactivity of Aplisol compared to reference standard PPD-S2.
Description: Reference standard PPD-S2 formulated to contain different dose concentrations.
Study: NCT02714621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
Study: NCT02000674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine : 1mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium : 1.2 mg/kg
Study: NCT02280265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation Factor VIII for injection
Description: Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
Study: NCT00302731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol , estriol , progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol, progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol, progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: equine estrogens m-progesteroneacetate
Study: NCT03054311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Matters
Study: NCT02513576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy exercises
Description: Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
Study: NCT05375058

Intervention type: OTHER
Intervention: Observational Study
Description: Observational Study; the study did not involve any interventions
Study: NCT05921942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg twice daily or 1000 mg once daily
Study: NCT01180452

Intervention type: PROCEDURE
Group type: OTHER
Intervention: enteroscopy
Description: endoscopic enteroscopy to do biopsies on jejunum
Study: NCT00943566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Release Morphine Sulfate
Description: Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
Study: NCT02033369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
Study: NCT05655130

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: standard of care surgery
Study: NCT01194167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
Study: NCT01641952

Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
Study: NCT00527410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 744
Description: Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
Study: NCT02547532

Intervention type: OTHER
Intervention: collection of sputum

Intervention type: OTHER
Intervention: collection of sputum
Study: NCT01812564

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Platelet Poor Plasma (PPP)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma (PRP)
Study: NCT02297867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADSCs
Description: autologous ADSCs
Study: NCT01569568

Intervention type: OTHER
Intervention: MRI scanning
Description: 1H MRS, DTI, FMRI

Intervention type: OTHER
Intervention: MRI scanning
Description: 1H MRS, DTI, FMRI

Intervention type: BEHAVIORAL
Intervention: Cognitive testing
Description: Behavioral testing
Study: NCT02547532

Intervention type: OTHER
Intervention: collection of sputum

Intervention type: OTHER
Intervention: collection of sputum

Intervention type: OTHER
Intervention: collection of sputum
Study: NCT01094015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine-prilocaine cream
Description: Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gel application for the transmission of ultrasound
Description: 3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
Study: NCT00428233

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Leukemia cell harvest
Description: Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
Study: NCT03277066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Active Topical Patch 1
Description: HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Active Topical Patch 2
Description: HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
Study: NCT01569568

Intervention type: BEHAVIORAL
Intervention: Cognitive testing
Description: Behavioral testing
Study: NCT00816712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Testosterone 300 mg, intramuscular injection
Description: Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Testosterone 100 mg, Intramuscular injection
Description: Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo given by Intramuscular Injection
Description: Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection.
Study: NCT01639846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for RX-10045 arm
Description: Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
Study: NCT04656262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is formulated as coated tablets of 50mg for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
Study: NCT03277066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
Study: NCT01880320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD0271 0.3% / CD1579 2.5%
Study: NCT02417987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Volume injection
Description: Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: High Volume injection
Description: Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous conditioned plasma (ACP)
Description: Injection with 4 mls of ACP around the tendon

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Autologous conditioned plasma (ACP)
Description: Injection with 4 mls of ACP around the tendon
Study: NCT03014843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: 20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone Bromide
Description: 12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
Study: NCT04991207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Oral Tracleer (bosentan) 125 mg film coated tablets
Study: NCT01880320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD0271 0.1% / CD1579 2.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Gel Vehicle
Study: NCT02850666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary process drama
Description: Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
Study: NCT04079699

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: Measuring biomarkers in blood and urine samples

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard biopsy
Description: Histological examination of tissue biopsies
Study: NCT04991207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bosentan
Description: Oral Tracleer (bosentan) 125 mg film coated tablets
Study: NCT03355612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib: 500 mg, qd, po, last 180 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
Study: NCT03143465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin Gene-Related Peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00734916

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral lipid emulsion (Omegaven)
Description: Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral lipid emulsion (Intralipid)
Description: Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Parental lipid emulsion (Saline 0.9%)
Description: Placebo (Saline 0.9%), same volume/hr as lipid emulsions
Study: NCT01540721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed paracetamol
Description: marketed formulation
Study: NCT04044742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Receiving Resiniferatoxin injection
Study: NCT03563170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine